Senin, 22 November 2010

Muehrcke's Lines

A 29-year-old woman with no significant medical history developed anasarca over the course of approximately 2 weeks. On the basis of renal biopsy, a diagnosis of minimal change disease was made. Her nephrotic syndrome was poorly responsive to steroid therapy, and despite high doses of prednisone of up to 120 mg/d, her serum albumin and proteinuria remained 1 g/dL and 10 g/d, respectively. Approximately 1 month after the onset of her symptoms, she developed transverse, nonpalpable, white lines on all her fingernails (Figure). These nail changes are consistent with a diagnosis of Muehrcke's lines.

To read this article in its entirety, please visit our website.

-- Nicholas Short, BA, Chirayu Shah, MD

This article originally appeared in the November 2010 issue of The American Journal of Medicine.

Kamis, 18 November 2010

Managing Myocardial Infarction in the Elderly: What Should the Clinician Do?

As the American population progressively ages, the number of elderly who suffer an acute myocardial infarction (MI) is increasing. These days, it is not uncommon for me to be caring for a number of patients 80 years old or more in our coronary care unit. The evident and potential frailty of these individuals can make their care complex. Recent publications have focused on the presentation and results of therapy in these elderly patients, as well as pathophysiologic differences between older and younger patients with acute MI.

Not surprisingly, elderly patients with acute MI have a worse prognosis as compared with younger individuals.

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD
Editor-in-Chief, The American Journal of Medicine

This article originally appeared in the November 2010 issue of The American Journal of Medicine.

Selasa, 16 November 2010

Lactation and Maternal Risk of Type 2 Diabetes: A Population-based Study

Risk of type 2 diabetes increases when childbirth is followed by less than one month of breastfeeding. This effect is independent of physical activity and body mass index later in life. Physicians should encourage breastfeeding.

Abstract

Background

Lactation has been associated with improvements in maternal glucose metabolism.

Methods
We explored the relationships between lactation and risk of type 2 diabetes in a well-characterized, population-representative cohort of women, aged 40-78 years, who were members of a large integrated health care delivery organization in California and enrolled in the Reproductive Risk factors for Incontinence Study at Kaiser (RRISK), between 2003 and 2008. Multivariable logistic regression was used to control for age, parity, race, education, hysterectomy, physical activity, tobacco and alcohol use, family history of diabetes, and body mass index while examining the impact of duration, exclusivity, and consistency of lactation on risk of having developed type 2 diabetes.

Results
Of 2233 women studied, 1828 were mothers; 56% had breastfed an infant for ≥1 month. In fully adjusted models, the risk of type 2 diabetes among women who consistently breastfed all of their children for ≥1 month remained similar to that of women who had never given birth (odds ratio [OR] 1.01; 95% confidence interval [CI], 0.56-1.81). In contrast, mothers who had never breastfed an infant were more likely to have developed type 2 diabetes than nulliparous women (OR 1.92; 95% CI, 1.14-3.27). Mothers who never exclusively breastfed were more likely to have developed type 2 diabetes than mothers who exclusively breastfed for 1-3 months (OR 1.52; 95% CI, 1.11-2.10).

Conclusions
Risk of type 2 diabetes increases when term pregnancy is followed by <1 month of lactation, independent of physical activity and body mass index in later life. Mothers should be encouraged to exclusively breastfeed all of their infants for at least 1 month.

To read this article in its entirety, please visit our website.

-- Eleanor Bimla Schwarz, MD, MS, Jeanette S. Brown, MD, Jennifer M. Creasman, MPH, Alison Stuebe, MD, MS, Candace K. McClure, PhD, Stephen K. Van Den Eeden, PhD, David Thom, MD, PhD

This article originally appeared in the September 2010 issue of The American Journal of Medicine.

Rabu, 03 November 2010

Inhaled Corticosteroids and the Risks of Diabetes Onset and Progression

In patients with respiratory disease, inhaled corticosteroid use is associated with modest increases in the risks of diabetes onset and diabetes progression. The risks are more pronounced at the higher doses currently prescribed in the treatment of chronic obstructive pulmonary disease.

Abstract

Background


Systemic corticosteroids are known to increase diabetes risk, but the effects of high-dose inhaled corticosteroids are unknown. We assessed whether the use and dose of inhaled corticosteroids increase the risk of diabetes onset and progression.

Methods

We formed a new-user cohort of patients treated for respiratory disease during 1990-2005, identified using the Quebec health insurance databases and followed through 2007 or until diabetes onset. The subcohort treated with oral hypoglycemics was followed until diabetes progression. A nested case-control analysis was used to estimate the rate ratios of diabetes onset and progression associated with current inhaled corticosteroid use, adjusted for age, sex, respiratory disease severity, and co-morbidity.

Results

The cohort included 388,584 patients, of whom 30,167 had diabetes onset during 5.5 years of follow-up (incidence rate 14.2/1000/year), and 2099 subsequently progressed from oral hypoglycemic treatment to insulin (incidence rate 19.8/1000/year). Current use of inhaled corticosteroids was associated with a 34% increase in the rate of diabetes (rate ratio [RR] 1.34; 95% confidence interval [CI], 1.29-1.39) and in the rate of diabetes progression (RR 1.34; 95% CI, 1.17-1.53). The risk increases were greatest with the highest inhaled corticosteroid doses, equivalent to fluticasone 1000 μg per day or more (RR 1.64; 95% CI, 1.52-1.76 and RR 1.54; 95% CI, 1.18-2.02; respectively).

Conclusions

In patients with respiratory disease, inhaled corticosteroid use is associated with modest increases in the risks of diabetes onset and diabetes progression. The risks are more pronounced at the higher doses currently prescribed in the treatment of chronic obstructive pulmonary disease.

To read this article in its entirety, please visit our website.

-- Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc

This article originally appeared in the November 2010 issue of The American Journal of Medicine.

Senin, 11 Oktober 2010

Aortic Stenosis in the 21st Century

When I was a medical student more than 40 years ago, aortic stenosis was almost invariably the result of rheumatic heart disease. Today, however, rheumatic aortic valve disease has almost vanished in the US. Nevertheless, aortic stenosis is still a common entity in our hospitals. What accounts for this change in the etiology of aortic stenosis and why is it still so common?

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD

This article originally appeared in the October 2010 issue of The American Journal of Medicine.

Sabtu, 09 Oktober 2010

A Plethora of Protein

Presentation

A 61-year-old man had long been plagued by symptoms of atopy and connective tissue disease when he presented with an 18-month history of soft, compressible nodules on both shins. His past history included atopic eczema since adolescence, asthma, hay fever, and hypertension. Two years earlier he experienced spontaneous venous thrombosis in the right arm. He also had elements of CREST syndrome, a constellation that includes calcinosis, Raynaud's syndrome, esophageal dysmotility, sclerodactyly, and telangiectasias. Our patient had a 10-year history of Raynaud's phenomenon, facial telangiectasias, reduced oral aperture, and esophageal reflux.

Assessment

General examination revealed pitting edema of the face, hands, and lower legs, and bilateral cauliflower ear deformity (Figure 1). This had been present for 10 years, without prior trauma and with no clinical features of chondritis. The patient did not have macroglossia.

What's the diagnosis?

To read this article in its entirety, please visit our website.

-- Diona L. Damian, MBBS, PhD, Jim V. Bertouch, MBBS, MD

This article originally appeared in the October 2010 issue of The American Journal of Medicine.


Kamis, 07 Oktober 2010

Adherence to Oral Contraception in Women on Category X Medications

Despite the added risk associated with unintended pregnancy, many women who receive Category X medications have refill patterns suggesting nonadherence to oral contraception. Compared with all women age 18-44, women receiving teratogenic medications do not have better adherence to oral contraception.

Abstract

Background

Over 6% of women become pregnant when taking teratogenic medications, and contraceptive counseling appears to occur at suboptimal rates. Adherence to contraception is an important component in preventing unwanted pregnancy and has not been evaluated in this population. We undertook a pharmacy claims-based analysis to evaluate the degree to which women of childbearing age who receive Category X medications adhere to their oral contraception.

Methods

We evaluated the prescription medication claims for over 6 million women, age 18-44 years, with prescription benefits administered by a pharmacy benefits manager. Women with 2 or more claims for a Category X medication and 2 or more claims for oral contraception were evaluated in further detail. Adherence to oral contraception was measured by analyzing pharmacy claims. Multivariable logistic regression was performed to identify factors associated with adherence.

Results

There were 146,758 women of childbearing age who received Category X medications, of which 26,136 also took oral contraceptive medication. Women who received Category X medications were prescribed oral contraception (18%) at rates similar to others of childbearing age (17%). Women prescribed both Category X and oral contraception demonstrated adherence similar to the overall population. Age, class of Category X medication, number of medications, prescriber's specialty, and ethnicity correlated with lower adherence rates.

Conclusions

Despite added risk associated with unintended pregnancy, many women who receive Category X medications have refill patterns suggesting nonadherence to oral contraception. Compared with all women age 18-44 years, women receiving teratogenic medications do not have better adherence to oral contraception.

To read this article in its entirety, please visit our website.

--Amy Steinkellner, PharmD, William Chen, PhD, MPH, Shannon E. Denison, MA

This article originally appeared in the October 2010 issue of The American Journal of Medicine.


Senin, 30 Agustus 2010

Obesity and Prostate Cancer Detection: Insights from Three National Surveys

Obese men tend to have lower Prostate Specific Antigen scores, resulting in fewer referrals for biopsies. Consequently, obese men have higher rates of prostate cancer progression. This study recommends that physicians consider a patient’s Body Mass Index when considering a biopsy referral.



Abstract

Background




Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys.



Methods



We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n = 845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n = 2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n = 4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories.



Results



Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3% vs 8%; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P = .24). However, among men who had PSA tests, 11% of men with BMI >30 versus 16% with BMI <25, achieved a PSA threshold of 4 ng/mL; P = .01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI < 25 in NHIS participants (4.6% vs 5.8%; P = .05).



Conclusions



Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.



To read this article in its entirety, please visit our website.



-- Niyati Parekh, PhD, RD, Yong Lin, PhD, Robert S. DiPaola, MD, Stephen Marcella, MD, MPH, Grace Lu-Yao, PhD, MPH



This article originally appeared in the September 2010 issue of The American Journal of Medicine.

Jumat, 27 Agustus 2010

Balancing Work, Family and Friends, and Lifestyle

Discussing the balance in a person's life resembles conversations about managing stressful times. As I write this, my daughter, Eva, an accountant and tax attorney, is in the final phase of her stressful and very hectic “busy season” as the April 15th tax deadline draws near. Some people think of those stressful times as periods in which their work/life/family–friends balance is unbalanced, and personal and professional fulfillment seems very far away. The stresses in our lives often make us feel uncomfortable, nervous, and anxious. At these times we wish that our daily activities could meld better so that the stress-induced discomfort would fade away, and we would feel more balanced. Each individual has a different sense of what these entities entail, and each of us undoubtedly feels strongly about what causes stress in our life or how to balance work, play, and human relationships.

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD

This article originally appeared in the September 2010 issue of The American Journal of Medicine.

Senin, 23 Agustus 2010

Interactive CME Activities Linked to AJM's Website

Busy physicians can now earn Continuing Medical Education (CME) credits in the comfort of their own homes by accessing multimedia CME programs on the Journal's website.

Currently, 3 CME programs are available on our website:

CME The Foundation Role of Beta Blockers Across the Cardiovascular Disease Spectrum: A Year 2009 Update

CME Managing Gout in the Primary Care Setting: What You and Your Patients Need to Know

CME Fibromyalgia Syndrome: Practical Strategies for Improving Diagnosis and Patient Outcomes

The CME section of the website is updated periodically, so check back for future options or become a subscriber to this blog for Journal updates. Just click on the "subscribe to" button.

Rabu, 18 Agustus 2010

Supplements Provide Additional Information to AJM's Audience

You may know that The American Journal of Medicine is published monthly, but do you know that several times a year the Journal also publishes supplements on specific topics?

Supplements are collections of peer-reviewed research papers on a given area of medicine.

To date in 2010, the Journal has published 3 supplements that are available for free on our website.

July 2010
β-Blockers: Mechanistic Explanations for Class Pharmacodynamic and Therapeutic Heterogeneity

April 2010
Respiratory Infections in the Community: Evaluating Current Antibiotic Options

March 2010
Current Issues in the Treatment of Type 2 Diabetes

If your business or organization would like to sponsor a supplement, contact the Journal at editors@amjmed.org for information.

Jumat, 06 Agustus 2010

AJM In Press Online Feature Brings You the Latest Research Studies

Want the most recent clinical research studies from The American Journal of Medicine? Check out the in press online section of AJM's website.

As new research studies and reviews are accepted by the Journal, a select few are uploaded to the in press online section in advance of the publication date.

The in press online section also allows authors to be published quickly.

Rabu, 04 Agustus 2010

Learning to Write: A Personal Reflection

Many of you have asked me how someone's career can evolve to marry medicine and editing and writing. The story actually begins with learning to read. My father's sister, a frequent visitor in our home, was a first grade teacher who began teaching me to read when I was 3 years old. As a journalism major and later as a career journalist, my mother was chief proofreader and critic of any school writing project. But all that changed when I was 14 years old, and my mother, tiring of typing our school essays, enrolled my brother and me in a summer secretarial school typing class where I learned to touch type without looking at my fingers on the keyboard. At the time I had no idea how important this skill would become. In later years, I often jokingly told my mother that the “best thing she ever did for me was to enroll me in the secretarial typing class.” Although typing is not writing, this skill started to pay off in high school when I wrote for the school newspaper and literary magazine, and found that typing efficiency could lead to better writing and more effective self-editing. My mother continued to encourage me to write both literary and academic essays, and I found great satisfaction in doing so.

I became an editor during my freshman year in college by accident.

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD

This article originally appeared in the August 2010 issue of The American Journal of Medicine.

Prevalence and Characteristics of Tinnitus among US Adults

Although tinnitus is common in the US, little is known about its risk factors. Analysis of more than 14,000 people with self-reported tinnitus revealed that it is more prevalent among older adults, non-Hispanic whites, former smokers, and adults with hypertension, hearing impairment, loud noise exposure or generalized anxiety disorder.

Abstract
Background


Tinnitus is common; however, few risk factors for tinnitus are known.

Methods

We examined cross-sectional relations between several potential risk factors and self-reported tinnitus in 14,178 participants in the 1999-2004 National Health and Nutrition Examination Surveys, a nationally representative database. We calculated the prevalence of any and frequent (at least daily) tinnitus in the overall US population and among subgroups. Logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI) after adjusting for multiple potential confounders.

Results

Approximately 50 million US adults reported having any tinnitus, and 16 million US adults reported having frequent tinnitus in the past year. The prevalence of frequent tinnitus increased with increasing age, peaking at 14.3% between 60 and 69 years of age. Non-Hispanic whites had higher odds of frequent tinnitus compared with other racial/ethnic groups. Hypertension and former smoking were associated with an increase in odds of frequent tinnitus. Loud leisure-time, firearm, and occupational noise exposure also were associated with increased odds of frequent tinnitus. Among participants who had an audiogram, frequent tinnitus was associated with low-mid frequency (OR 2.37; 95% CI, 1.76-3.21) and high frequency (OR 3.00; 95% CI, 1.78-5.04) hearing impairment. Among participants who were tested for mental health conditions, frequent tinnitus was associated with generalized anxiety disorder (OR 6.07; 95% CI, 2.33-15.78) but not major depressive disorder (OR 1.58; 95% CI, 0.54-4.62).

Conclusions

The prevalence of frequent tinnitus is highest among older adults, non-Hispanic whites, former smokers, and adults with hypertension, hearing impairment, loud noise exposure, or generalized anxiety disorder. Prospective studies of risk factors for tinnitus are needed.

To read this article in its entirety, please visit our website.

-- Josef Shargorodsky, MD, Gary C. Curhan, MD, ScD, Wildon R. Farwell, MD, MPH

This article originally appeared in the August 2010 issue of The American Journal of Medicine

Kamis, 01 Juli 2010

A Review of Clinical Guidelines with Some Thoughts about Their Utility and Appropriate Use

“Guidelines” has become one of the most common buzzwords for medical practitioners in the 21st century in our search to define and measure quality in health care. Physicians and other health care workers, administrators, bureaucrats, and politicians have all become involved in discussions concerning the attainment of quality in our medical care system. This is not a new movement. Quality assurance, often referred to as best practices, has been a hot topic in hospitals and health care systems for more than 2 decades. Recently, politicians and bureaucrats in the federal government have begun discussing ways to improve health outcomes in the US, considering various combinations of strategic initiatives that would include electronic health records with embedded recommendations for best practices in diagnosis and therapy.

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD

This article originally appeared in the July 2010 issue of The American Journal of Medicine.

Migraine Headache and Ischemic Stroke Risk: An Updated Meta-analysis

A history of migraine headache is associated with a 2-fold increased risk of ischemic stroke. Ischemic stroke risk may be further increased in patients with aura and in women. Risk factor reduction should be considered in high-risk patients who have other modifiable stroke risk factors.

Abstract
Background


Observational studies, including recent large cohort studies that were unavailable for prior meta-analysis, have suggested an association between migraine headache and ischemic stroke. We performed an updated meta-analysis to quantitatively summarize the strength of association between migraine and ischemic stroke risk.

Methods

We systematically searched electronic databases, including MEDLINE and EMBASE, through February 2009 for studies of human subjects in the English language. Study selection using a priori selection criteria, data extraction, and assessment of study quality were conducted independently by reviewer pairs using standardized forms.

Results

Twenty-one (60%) of 35 studies met the selection criteria, for a total of 622,381 participants (13 case-control, 8 cohort studies) included in the meta-analysis. The pooled adjusted odds ratio of ischemic stroke comparing migraineurs with nonmigraineurs using a random effects model was 2.30 (95% confidence interval [CI], 1.91-2.76). The pooled adjusted effect estimates for studies that reported relative risks and hazard ratios, respectively, were 2.41 (95% CI, 1.81-3.20) and 1.52 (95% CI, 0.99-2.35). The overall pooled effect estimate was 2.04 (95% CI, 1.72-2.43). Results were robust to sensitivity analyses excluding lower quality studies.

Conclusions

Migraine is associated with increased ischemic stroke risk. These findings underscore the importance of identifying high-risk migraineurs with other modifiable stroke risk factors. Future studies of the effect of migraine treatment and modifiable risk factor reduction on stroke risk in migraineurs are warranted.

To read this article in its entirety, please visit our website.

-- June T. Spector, MD, MPH, Susan R. Kahn, MD, MSc, Miranda R. Jones, BA, Monisha Jayakumar, BDS, MPH, Deepan Dalal, MBBS, MPH, Saman Nazarian, MD

This article originally appeared in the July 2010 issue of The American Journal of Medicine.

Kamis, 10 Juni 2010

The Effectiveness of Outpatient Appointment Reminder Systems in Reducing No-Show Rates

Outpatient automated reminder systems are less effective in reducing no-show rates compared to receiving a reminder from live, clinic staff. Type of reminder, age, visit type, wait time, division specialty, and insurance type are significant predictors of no-shows to appointments.

Abstract
Background


Patients who do not keep physician appointments (no-shows) represent a significant loss to healthcare providers. For patients, the cost includes their dissatisfaction and reduced quality of care. An automated telephone appointment reminder system may decrease the no-show rate. Understanding characteristics of patients who miss their appointments will aid in the formulation of interventions to reduce no-show rates.

Methods

In an academic outpatient practice, we studied patient acceptance and no-show rates among patients receiving a clinic staff reminder (STAFF), an automated appointment reminder (AUTO), and no reminder (NONE). Patients scheduled for appointments in the spring of 2007 were assigned randomly to 1 of 3 groups: STAFF (n=3266), AUTO (n=3219), or NONE (n=3350). Patients in the STAFF group were called 3 days in advance by front desk personnel. Patients in the AUTO group were reminded of their appointments 3 days in advance by an automated, standardized message. To evaluate patient satisfaction with the STAFF and AUTO, we surveyed patients who arrived at the clinic (n=10,546).

Results

The no-show rates for patients in the STAFF, AUTO, and NONE groups were 13.6%, 17.3%, and 23.1%, respectively (pairwise, P<.01 by analysis of variance for all comparisons). Cancellation rates in the AUTO and STAFF groups were significantly higher than in the NONE group (P<.004). Appointment reminder group, age, visit type, wait time, division specialty, and insurance type were significant predictors of no-show rates. Patients found appointment reminders helpful, but they could not accurately remember whether they received a clinic staff reminder or an automated appointment reminder.

Conclusions

A clinic staff reminder was significantly more effective in lowering the no-show rate compared with an automated appointment reminder system.

To read this article in its entirety, please visit our website.

-- Amay Parikh, MD, MBA, MS, Kunal Gupta, MD, MBA, Alan C. Wilson, PhD, Karrie Fields, CPC, Nora M. Cosgrove, RN, John B. Kostis, MD

This article originally appeared in the June 2010 issue of The American Journal of Medicine.

The Risk of Stent Thrombosis after Coronary Arterial Stent Implantation

One of the most dreaded complications after percutaneous coronary arterial angioplasty is stent thrombosis. This serious untoward event usually results in acute myocardial infarction with high mortality. Stent thrombosis often occurs early, within 30 days of implantation, in patients who receive bare metal coronary arterial stents. However, patients undergoing drug-eluting stent implantation infrequently develop late stent thrombosis many months and even years after the deployment of these devices. Fortunately, stent thrombosis is a rather uncommon event.

Factors that favor stent thrombosis include technical problems during stent implantation; patients who undergo stent placement after an acute coronary syndrome or when diabetes mellitus is present; and patients with an intrinsic resistance to antiplatelet therapy.

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD, Karl B. Kern, MD, Gordon A. Ewy, MD

This article originally appeared in the June 2010 issue of The American Journal of Medicine.

Kamis, 03 Juni 2010

Appropriate Use of D-dimer in Hospital Patients

Abstract
D-dimer, the final product of plasmin-mediated degradation of fibrin-rich thrombi, has emerged as a simple blood test that can be used in diagnostic algorithms for the exclusion of venous thromboembolism. D-dimer also is used as a part of the diagnostic tests for disseminated intravascular coagulation, where excessive thrombin generation is the key pathophysiological factor. However, there are no robust data available at present on the use of this test to exclude venous thromboembolism in a hospital inpatient. Considerable confusion also exists among physicians about its appropriate use and interpretation in disseminated intravascular coagulation. This article focuses on the available evidence to guide the appropriate use of D-dimer in patients admitted to a hospital.

To read this article in its entirety, please visit our website.

-- Jecko Thachil, MD, David A. Fitzmaurice, MD, Cheng Hock Toh, MD

This article originally appeared in the January 2010 issue of The American Journal of Medicine.

Selasa, 25 Mei 2010

Management of Hepatitis C Virus-related Mixed Cryoglobulinemia

Mixed cryoglobulinemia is a chronic immune complex-mediated disease strongly associated with hepatitis C virus infection. Clinical features include skin lesions, glomerulonephritis, peripheral neuropathy, and widespread vasculitis.

Abstract
Mixed cryoglobulinemia is a chronic immune complex-mediated disease strongly associated with hepatitis C virus (HCV) infection. Mixed cryoglobulinemia is a vasculitis of small and medium-sized arteries and veins, due to the deposition of complexes of antigen, cryoglobulin and complement in the vessel walls. The main clinical features of mixed cryoglobulinemia vasculitis include the triad of palpable purpura, arthralgias, and weakness, and other pathological conditions such as glomerulonephritis, peripheral neuropathy, skin ulcers, and widespread vasculitis. The treatment of HCV-related mixed cryoglobulinemia is difficult due to the multifactorial origin and clinical polymorphism of the syndrome. It can be directed to eradicate the HCV infection, suppress the B-cell clonal expansion and cryoglobulin production, or ameliorate symptoms. The choice of the most appropriate treatment is strictly related to the assessment of disease activity, and to the extent and severity of organ involvement.

To read this article in its entirety, please visit our website.

-- F. Iannuzzella, A. Vaglio, G. Garini.

This article originally appeared in the May 2010 issue of The American Journal of Medicine.

Emphysematous Pyelonephritis Caused by Candida tropicalis

Emphysematous pyelonephritis is a severe necrotizing infection characterized by gas formation within the renal parenchyma, collecting system, and perinephric tissues.1, 2, 3 This condition commonly occurs in women with diabetes mellitus and obstructive uropathy.(1, 2, 3, 4, 5) Escherichia coli and Klebsiella are the most common organisms cultured.(1, 2, 3, 4, 5) Rarely, Candida species have been reported to cause emphysematous pyelonephritis.(6)

Case Report
A 51-year-old African-American transgender male with history of intravenous drug abuse presented to the emergency department with nausea, vomiting, and oliguria for 10 days. She had severe abdominal pain in the right upper quadrant and generalized weakness. She denied fever, dysuria, and flank pain.

To read this article in its entirety, please visit our website.

-- Prasanna V. Krishnasamy, Christopher Liby III

This article originally appeared in the April 2010 issue of The American Journal of Medicine.

Kamis, 06 Mei 2010

“Dear Editor: Can You Please Expedite My Manuscript's Publication in the AJM?”

Each week, I receive the message cited in the title from one or more of our authors whose manuscripts have been accepted and are scheduled for publication in The American Journal of Medicine. Reasoning behind these requests varies but often has to do with desires on the author's part for priority in the medical literature, grant application timing, and a variety of other reasonable and pressing issues. Of course, if we move this manuscript ahead in the publication queue, another author's publication date has to be delayed because we decide which material will be published in a specific issue a number of months in advance of the actual publication date. In an ideal world, we would publish manuscripts as soon as they had been accepted and copy edited by the team here in Tucson and in New York at Elsevier headquarters. However, the process leading to publication requires time spent in manuscript revision, copy editing, typesetting, proofreading, approval of the galley proofs by authors, and other more minor administrative issues related to the publication process. I actually have been very impressed with how quickly Elsevier and the printer who actually prints the Journal respond to our digitally transmitted publication materials.

In an effort to speed publication and to help our authors communicate with the medical scientific world as quickly as possible, we have instituted a process whereby manuscripts are posted on our journal website as soon as copy editing is finished, and the authors approve the galley proof.

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD, Editor-in-Chief

This article originally appeared in the May 2010 issue of The American Journal of Medicine.

Senin, 03 Mei 2010

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?

In this study, less than half of patients with atrial fibrillation/atrial flutter received warfarin following their diagnosis. Similar proportions of patients with low, moderate, and high stroke risk received warfarin. This suggests that it may be underused in patients with high stroke risk and overused among patients with low stroke risk.

Abstract
Background

Clinical guidelines for the management of atrial fibrillation and atrial flutter provide recommendations for anticoagulation based on patients' overall risk of stroke. To determine the real-world compliance of physicians with these recommendations, we conducted a retrospective cohort study examining the utilization of warfarin in atrial fibrillation/flutter patients by stroke risk level.

Methods
Patients with a qualifying atrial fibrillation/flutter diagnosis during ≥18 months' continuous enrollment between January 2003 and September 2007, and with ≥6 months' eligibility after the first atrial fibrillation/flutter diagnosis, were identified from the US MarketScan database (Thomson Reuters, New York, NY). Warfarin use within 30 days of the first diagnosis was assessed according to stroke risk, estimated using the Congestive heart failure, Hypertension, Age >75 years, Diabetes, Stroke (CHADS2) score.

Results
Of 171,393 patients included in the analysis, 20.0% had a CHADS2 score of 0 (low risk), 61.6% a score of 1-2 (moderate risk), and 18.4% a score of 3-6 (high risk). Warfarin, recommended for high stroke-risk patients, was given to only 42.1% of those with a CHADS2 score of 3-6. A similar percentage of patients with moderate (43.5%) or low stroke risk (40.1%) received warfarin. Only 29.6% of high-risk, 33.3% of moderate-risk, and 34.1% of low-risk patients who were started on warfarin received uninterrupted therapy for 6 months following their initial prescription.

Conclusions
These data suggest that guideline recommendations that anticoagulation should be provided in accordance with stroke risk in atrial fibrillation patients are not routinely followed in clinical practice. The causes and clinical implications of under-utilization of anticoagulation in atrial fibrillation patients with high stroke risk warrant further study.

To read this article in its entirety, please visit our website.

-- Peter J. Zimetbaum, MD Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan Xiong, MS, Jay Lin, PhD, Prajesh Kothawala, MD, MPH, Matthew Emons, MD, MBA

This article originally appeared in the May 2010 issue of The American Journal of Medicine.

Minggu, 04 April 2010

Sunshine: Clinical Friend or Foe?

But soft! What light through yonder window breaks? It is the east, and Juliet is the sun! Arise, fair sun, and kill the envious moon …

Shakespeare, W: Romeo and Juliet, Act II, Scene II.

When you live in Arizona, the sun is always with you. Living here makes it easy to understand that the sun has been a central factor in human existence, iconography, and a variety of religions in ancient Egypt, Indo-Europe, and Meso-America since the beginning of recorded or archaeologically defined history. (1,2)

The first scientific writings concerning the benefit of sun therapy emanated from the investigations of Niels Ryberg Finsen, who won the Nobel Prize for his work with heliotherapy (Helios in ancient Greek = sun).(3) Finsen observed the effect of sunlight on his own fragile health. He supplemented these personal observations with experiments on animals and eventually began a series of clinical trials using natural and artificial sunlight therapy for 2 skin conditions: smallpox and tuberculosis of the skin. The dermatologic lesions of both conditions responded to natural and artificial sunlight exposure in these experiments, eventually leading to the Nobel Prize in 1903.(4)

To read this article in its entirety, please visit our website.

-- Joseph S. Alpert, MD, Editor-in-Chief

This article originally appeared in the April 2010 issue of The American Journal of Medicine.

Long-acting Beta-Agonists with and without Inhaled Corticosteroids and Catastrophic Asthma Events

There is a 3-fold increase in asthma-related intubations and deaths in those taking long-acting beta-agonists with concomitant corticosteroids compared to corticosteroids alone, according to this meta-analysis.

Abstract
Background

It is unclear whether long-acting β-agonists with concomitant inhaled corticosteroids increase asthma-related intubations and deaths. We pooled data on long-acting β-agonists with variable and concomitant inhaled corticosteroids to evaluate the risk for catastrophic asthma events.

Methods
We conducted searches of electronic databases, the US Food and Drug Administration website, clinical-trials registries, and selected references through December 2008. We analyzed randomized controlled trials in patients with asthma, which lasted at least 3 months, evaluated long-acting β-agonists compared with placebo or long-acting β-agonists with inhaled corticosteroids compared with corticosteroids alone, and included at least 1 catastrophic event, defined as asthma-related intubation or death.

Results
In pooled trial data that included 36,588 participants, long-acting β-agonists increased catastrophic events 2-fold (Peto odds ratio [OR] 2.10; 95% confidence interval [CI], 1.37-3.22). Statistically significant increases were seen for long-acting β-agonists with variable corticosteroids compared with placebo (OR 1.83; 95% CI, 1.14-2.95) and for concomitant treatment with corticosteroids compared with corticosteroids alone (OR 3.65; 95% CI, 1.39-9.55). Similar increases in risk were seen for variable and concomitant corticosteroid use, salmeterol and formoterol, and children and adults. When the analysis was restricted to trials with controlled corticosteroid use, given as part of the study intervention, concomitant treatment still increased catastrophic events compared with corticosteroids alone (OR 8.19; 95% CI, 1.10-61.18).

Conclusion
Long-acting β-agonists increase the risk for asthma-related intubations and deaths, even when used in a controlled fashion with concomitant inhaled corticosteroids.

To read this article in its entirety, please visit our website.

-- Shelley R. Salpeter, MD, FACP, Andrew J. Wall, MD, Nicholas S. Buckley

This article originally appeared in the April 2010 issue of The American Journal of Medicine.

Rabu, 03 Maret 2010

We Can Reduce US Health Care Costs

The primary reason that the US needs health care reform is that we pay more for health care than any other country in the world; yet our health outcomes are below that of other western nations.(1) Our health outcomes are suboptimal because millions of Americans have limited access to ongoing primary and preventive care because they can't afford our health insurance.

Reducing Administrative Costs

We spend more than a third of our health care dollars on overhead and administration: billing, advertising, profits, and bonuses for health care executives.(2, 3) Administrative costs in countries such as Canada that have a single payer (non-profit national health insurance) are half as much as in the US.(2) If we had a single payer instead of hundreds of insurers with thousands of different plans, we would save 15% of our health care costs. Fifteen per cent of trillions adds up!

A Price Waterhouse Coopers study reported that our complex, fragmented health care delivery system wastes $210 billion per year on unnecessary billing and administrative costs.(4) The ultimate solution to our excessive health care costs is national health insurance: Medicare for all(5); but that won't happen–at least not in the very near future. What can we do to decrease health care costs now?

To read this article in its entirety, please visit our website.

-- James E. Dalen, MD, MPH

This article originally appeared in the March 2010 issue of The American Journal of Medicine.

Analgesic Use and the Risk of Hearing Loss in Men

Regular use of aspirin, acetaminophen and nonsteroidal anti-inflammatory drugs, the most commonly used drugs in the US, may increase risk of hearing loss in men.

Abstract
Background

Hearing loss is a common sensory disorder, yet prospective data on potentially modifiable risk factors are limited. Regularly used analgesics, the most commonly used drugs in the US, may be ototoxic and contribute to hearing loss.

Methods
We examined the independent association between self-reported professionally diagnosed hearing loss and regular use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen in 26,917 men aged 40-74 years at baseline in 1986. Study participants completed detailed questionnaires at baseline and every 2 years thereafter. Incident cases of new-onset hearing loss were defined as those diagnosed after 1986. Cox proportional hazards multivariate regression was used to adjust for potential confounding factors.

Results
During 369,079 person-years of follow-up, 3488 incident cases of hearing loss were reported. Regular use of each analgesic was independently associated with an increased risk of hearing loss. Multivariate-adjusted hazard ratios of hearing loss in regular users (2+ times/week) compared with men who used the specified analgesic <2 times/week were 1.12 (95% confidence interval [CI], 1.04-1.20) for aspirin, 1.21 (95% CI, 1.11-1.33) for NSAIDs, and 1.22 (95% CI, 1.07-1.39) for acetaminophen. For NSAIDs and acetaminophen, the risk increased with longer duration of regular use. The magnitude of the association was substantially higher in younger men. For men younger than age 50 years, the hazard ratio for hearing loss was 1.33 for regular aspirin use, 1.61 for NSAIDs, and 1.99 for acetaminophen.

Conclusions
Regular use of aspirin, NSAIDs, or acetaminophen increases the risk of hearing loss in men, and the impact is larger on younger individuals.

To read this article in its entirety, please visit our website.

-- Sharon G. Curhan, MD, ScM, Roland Eavey, MD, Josef Shargorodsky, MD, Gary C. Curhan, MD, ScD

This article originally appeared in the March 2010 issue of The American Journal of Medicine.

A Post-cure Complication

Long-term drug therapy for hepatitis C virus (HCV) infection would prove to have persistent effects—both desirable and undesirable. A 29-year-old woman with chronic hepatitis C, genotype 4, was to embark on a treatment regimen of oral ribavirin, 1000 mg, once daily and subcutaneous injections of pegylated interferon alfa-2b, 80 μg, once a week. At her initial physical examination, she had a body mass index of 26 (25-29 indicates overweight). Laboratory results showed that her alanine transaminase level, at 88 IU/mL, was well above the normal reference value (<31 IU/mL). Her albumin level and prothrombin time were within the normal range. She had no other relevant medical or family history.



In the first month, the patient reported anorexia, asthenia, and a weight loss of 8.8 lb (4 kg). Therapy continued, and just before the 48-week treatment period ended, she developed signs of bilateral lipoatrophy at the interferon injection site on her abdomen (Figure).



To read this article in its entirety, please visit our website.



-- Joana Nunes, MD, Rui Tato Marinho, MD, PhD, José Velosa, MD, PhD



This article originally appeared in the March 2010 issue of The American Journal of Medicine.



Selasa, 16 Februari 2010

AJM Advances in Impact Factor and PERC Readership Analysis

The American Journal of Medicine (AJM) recently received the good news that our impact factor now exceeds 5.0. AJM has been steadily moving up in this index; our score has risen each of the last 5 years, since the current editorial team took over the Journal.

In addition, AJM's independent PERC readership analysis also has improved substantially.

In 2004, only 14% of internists in the US reported that they spent any time reading the AJM. In this year's analysis, the percentage rose to 46%, passing the readership score for the Archives of Internal Medicine and closing in rapidly on the readership score for the Annals of Internal Medicine.

We, at the AJM editorial office, are pleased and proud of the Journal's progress. We are committed to continuing this fine performance.

Senin, 08 Februari 2010

Why Are We Ignoring Guideline Recommendations?

In the current issue of The American Journal of Medicine, Lopes et al(1) report discouraging news. They examined a large cohort of patients taken from 3 large randomized double-blind clinical trials and asked the question: “Are patients in these trials who were in atrial fibrillation being treated with antithrombotic therapy in accordance with widely accepted guidelines?” Unfortunately, only a small percentage (13.5%) of the patients with atrial fibrillation in these trials were, in fact, receiving indicated prophylactic antithrombotic therapy with warfarin. This is not an unusual finding. Many other studies have documented that guideline recommendations are followed for a disappointingly small portion of inpatients and outpatients.(2, 3) It has become clear that in daily clinical practice, guideline advice is often ignored or overlooked. What can be the explanation for this lack of compliance with evidence-based counsel? Guidelines are written by acknowledged experts in the areas covered, and the published results of guidelines are widely disseminated. Why don't physicians follow this advice? Surely, it is not because as a group we are careless or don't care about the results of carefully conducted clinical trials.

I have given this topic a great deal of thought in recent months, and my personal opinion is that neither negligence nor hostility to guidelines underlies poor physician compliance. Rather, I believe that a number of other factors help to explain the observed failure to use evidence-based guideline information:

1. Currently, there are literally hundreds and hundreds of guidelines available. These have all been carefully prepared by a variety of different professional societies. Some of these guidelines are quite long, at times exceeding 300 pages in length. Considering the number of guidelines and their size, it is not surprising that busy physicians do not have time to peruse, no less absorb, the presented material. Furthermore, in a hectic physician work day with its constant interruptions, one can easily understand why guideline-recommended interventions might be overlooked.

2. Clinicians in practice develop a series of personal “tried and true” approaches for managing the disease entities commonly seen in their daily work. Once established and thought to be successful, the use of these personal approaches becomes second nature to the physician. Changing these personal protocols feels like an unnecessary imposition given the many demands already craving attention in the busy clinician's work day. Again, given these comfortable patterns of practice, it is not surprising that new evidence-based clinical approaches would not be adopted easily.

3. Physician training, particularly in the past, emphasized individual patient therapeutic regimens with an avoidance of rigid “cookbook”-style order sets. Thus, many physicians think that a rigid “cookbook” style of medical practice, including the use of standard order sets based on guideline recommendations, represents an improper approach to patient care.

4. With specific reference to preventive antithrombotic therapy in patients with atrial fibrillation, patients and doctors dislike warfarin therapy, the most widely recommended antithrombotic therapy for patients with atrial fibrillation. The many dietary and pharmacologic caveats associated with warfarin therapy, the need for frequent monitoring of drug effect, and the fear for both patient and physician of unexpected bleeding complications make this agent one of the least desired therapeutic recommendations in most practices, including my own.

5. Finally, large, randomized, global, double-blind trials produce results that reflect outcomes for the majority, but not all of the patients, in that particular trial. There are usually a substantial minority of patients in each of these trials, the results of which lead to evidence-based guideline recommendations, who do not behave like the majority. Physicians may think that their particular patients do not fit the pattern observed in the large clinical trials. To some extent they might be perfectly right in this assumption. This attitude might lead some doctors to advise a therapeutic protocol different from that suggested by the results of the large, “gold standard,” randomized, double-blind clinical trials.

Whatever reasoning affects clinical decision making in these patients, the end result is often nonadherence to guidelines. Unfortunately, guideline-directed therapy for a particular condition has been shown to lead to better clinical outcomes compared with “eminence-based,” personally derived, therapeutic strategies. In general, the majority of patients with a particular entity would almost certainly benefit if guideline-directed therapy were universally applied. This is the reasoning behind many quality initiatives. As noted above, research in this arena has supported the idea that guideline-based therapy produces better clinical outcomes compared with arbitrarily selected therapeutic regimens. If we accept the latter 2 statements, the question then arises, “how can we get doctors to adhere more closely to evidence-based therapy as suggested in clinical guidelines?”

Our experience at the University of Arizona College of Medicine has suggested one potential solution to the conundrum just described, that is, more liberal use of standard order sets embedded in electronic medical records and computer order systems. An example of how such standardization might improve clinical quality is as follows. A few years ago, it was noted by our quality department at the University Medical Center that documentation of counseling concerning cessation of tobacco use was often lacking in the charts of our patients discharged after an acute myocardial infarction. To remedy this problem, a requirement was placed in our discharge order set for these patients to receive this counseling. The patient could not be discharged from the hospital until a doctor or nurse involved in the patient's care had checked a box in the electronic orders stating that such appropriate advice concerning smoking cessation had indeed been carried out. This small and simple alteration in our discharge order set guaranteed that all such patients received tobacco cessation recommendations.

This change in our approach to smoking cessation counseling resulted in essentially 100% compliance with the need to give this advice. Why not use the same strategy for other order sets with similar guideline-advised therapeutic orders placed in the discharge orders together with drop-down boxes detailing reasons why a particular intervention was not used? The full order set would not be accepted until all such queries had been satisfactorily managed. The introduction of evidence-based orders as well as statements detailing why exceptions to these orders were made would ensure that the clinician had been made aware of the importance of dealing with these interventions. In this manner it would be possible to ensure a very high rate of compliance with evidence-based guideline recommendations. Presumably, this would also lead to improved quality of care for these patients.

As always, I'd be interested in hearing your comments on this important topic. Feel free to post a comment on our blog.

References
1. Lopes RD, Starr A, Pieper CF, et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010;123:134–140.

2. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines?. JAMA. 1999;282:1458–1465.

3. Bach DS, Awais M, Gurm HS, Kohnstamm S. Failure of guideline adherence for intervention in patients with severe mitral regurgitation. J Am Coll Cardiol. 2009;54:860–865.

-- Joseph S. Alpert, MD
Editor-in-Chief, The American Journal of Medicine

This article originally appeared in the February 2010 issue of The American Journal of Medicine.

Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes

Warfarin is associated with better 6-month outcomes among patients with atrial fibrillation complicating an acute coronary syndrome, but its use is not related to Congestive heart failure, Hypertension, Age>75 years, Diabetes, Prior Stroke/transient ischemic attack (CHADS2) score or bleeding risk.

Abstract

Background

We examined warfarin use at discharge (according to Congestive heart failure, Hypertension, Age > 75 years, Diabetes, Prior Stroke/transient ischemic attack score and bleeding risk) and its association with 6-month death or myocardial infarction in patients with post-acute coronary syndrome atrial fibrillation.

Methods
Of the 23,208 patients enrolled in the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy, Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network A, and Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors trials, 4.0% (917 patients) had atrial fibrillation as an in-hospital complication and were discharged alive. Cox proportional hazards models were performed to assess 6-month outcomes after discharge.

Results
Overall, 13.5% of patients with an acute coronary syndrome complicated by atrial fibrillation received warfarin at discharge. Warfarin use among patients with atrial fibrillation had no relation with estimated stroke risk; similar rates were observed across Congestive heart failure, Hypertension, Age > 75 years, Diabetes, Prior Stroke/transient ischemic attack (CHADS2) scores (0, 13%; 1, 14%; ≥ 2, 13%) and across different bleeding risk categories (low risk, 11.9%; intermediate risk, 13.3%; high risk, 11.1%). Among patients with in-hospital atrial fibrillation, warfarin use at discharge was independently associated with a lower risk of death or myocardial infarction within 6 months of discharge (hazard ratio 0.39; 95% confidence interval, 0.15-0.98).

Conclusion
Warfarin is associated with better 6-month outcomes among patients with atrial fibrillation complicating an acute coronary syndrome, but its use is not related to CHADS2 score or bleeding risk.

To read this article in its entirety, please visit our website.

-- Renato D. Lopes, MD, PhD, Aijing Starr, Carl F. Pieper, DPH, Sana M. Al-Khatib, MD, MHS, L. Kristin Newby, MD, MHS, Rajendra H. Mehta, MD, MS, Frans Van de Werf, MD, PhD, Kenneth W. Mahaffey, MD, Paul W. Armstrong, MD, Robert A. Harrington, MD, Harvey D. White, DSc, Lars Wallentin, MD, Christopher B. Granger, MD

This article originally appeared in the February 2010 issue of The American Journal of Medicine.

Aspirin for the Primary Prevention of Stroke and Myocardial Infarction: Ineffective or Wrong Dose?

More than 40 million Americans take aspirin for the primary or secondary prevention of myocardial infarction and stroke, including approximately half of all those aged 65 years or more.(1) The daily dose varies from 81 mg (1 baby aspirin) to 325 mg (1 adult aspirin). The efficacy of aspirin for the secondary prevention of myocardial infarction and stroke has been validated by multiple randomized clinical trials.(2)

The first randomized clinical trial to establish the efficacy of aspirin for primary prevention was the US Physicians Health study published in 1989.(3) More than 22,000 male US physicians were randomized to 325 mg of aspirin every other day versus placebo and followed for 5 years. The incidence of fatal or nonfatal myocardial infarction was 44% lower in those taking aspirin (odds ratio = 0.56; 95% confidence interval, 0.45-0.70; P < .0001). The decreased risk of myocardial infarction was present in those aged 50 years or more. There was no significant difference in mortality or stroke incidence.(3)

To read this article in its entirety, please visit our website.

-- James E. Dalen, MD, MPH

This article originally appeared in the February 2010 issue of The American Journal of Medicine.

More Thoughts on Tackling Obesity

I want to thank all the commentators for their insightful and excellent responses to my editorial on obesity. I agree with everything that was said including comments on how to create positive rewards (money) and negative conditioning (higher prices for high calorie junk foods) to assist in the battle against obesity. Our cafeteria here at the University Hospital is considering raising prices on unhealthy food choices in order to lower them on heart healthy selections. I also support the idea of a "sin" tax on high calorie junk food such as soft drinks that are loaded with one or another form of glucose. In the final analysis, education is going to be critical in this arena. We need to start teaching children about good nutritional choices in the very earliest school grades and continue the lessons right through high school and beyond. As the many respondents to the blog stated "We need to get serious about controlling obesity". Thanks again to all who wrote comments. Joseph Alpert, editor, AJM.

Selasa, 19 Januari 2010

Statins Decrease the Occurrence of Venous Thromboembolism in Patients with Cancer

In addition to cholesterol-lowering effect, statins exhibit anti-thrombotic and anti-inflammatory properties, which may affect coagulation cascade. In cancer patients, the use of statins decreased the odds of developing venous thromboembolism, when compared with non-statins users.

Abstract
Background

Recent data suggest a reduction in the occurrence of venous thromboembolism in select groups of patients who use statins. The objective of this study is to evaluate the impact of statin use on the occurrence of venous thromboembolism in patients with solid organ tumor.

Methods
We conducted a retrospective, case-control study reviewing 740 consecutive patients with a diagnosis of solid organ tumor who were admitted to the Albert Einstein Medical Center, Philadelphia, Penn, between October 2004 and September 2007. Patients treated with anticoagulation therapy before their first admission were excluded. The occurrence of venous thromboembolism, risk factors for venous thromboembolism, and statin use were recorded. Patients who never used statins or had used them for less than 2 months were relegated to the control group.

Results
The mean age of the study population was 65 years, and 52% of the patients were women and 76% were African American. The occurrence of venous thromboembolism was 18% (N = 132), and 26% (N = 194) were receiving statins. Among patients receiving statins, 8% (N = 16) developed a venous thromboembolism compared with 21% (N = 116) in the control group (odds ratio 0.33; 95% confidence interval, 0.19-0.57). A logistic regression analysis including risk factors for venous thromboembolism (metastatic disease, use of chemotherapy, immobilization, smoking, and aspirin use) along with statin use yielded the same results.

Conclusion
This study suggests that the use of statins is associated with a significant reduction in the occurrence of venous thromboembolism. This pleiotropic effect warrants further investigation.

To read this article in its entirety, please visit our website.

-- Danai Khemasuwan, MD, Matthew L. DiVietro, DO, Kawin Tangdhanakanond, MD, Sherry C. Pomerantz, PhD, Glenn Eiger, MD

This article originally appeared in the January 2010 issue of The American Journal of Medicine.

Care of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying Therapy

Hormone-modifying cancer therapy can lead to increased risk of metabolic syndrome. Vigilant screening and treatment for metabolic syndrome is an important component of care for cancer survivors.

Abstract
Emerging evidence implicates metabolic syndrome as a long-term cancer risk factor but also suggests that certain cancer therapies might increase patients' risk of developing metabolic syndrome secondary to cancer therapy. In particular, breast cancer and prostate cancer are driven in part by sex hormones; thus, treatment for both diseases is often based on hormone-modifying therapy. Androgen suppression therapy in men with prostate cancer is associated with dyslipidemia, increasing risk of cardiovascular disease, and insulin resistance. Anti-estrogen therapy in women with breast cancer can affect lipid profiles, cardiovascular risk, and liver function. As the number of cancer survivors continues to grow, treating physicians must be aware of the potential risks facing patients who have been treated with either androgen suppression therapy or anti-estrogen therapy so that early diagnosis and intervention can be achieved.

To read this article in its entirety, please visit our website.

-- Amanda J. Redig, PhD, Hidayatullah G. Munshi, MD

This article originally appeared in the January 2010 issue of The American Journal of Medicine.

'So, Doctor, What's So Bad About Being Fat?' Combating the Obesity Epidemic in the United States

Each week, many of my middle-aged patients ask me the question cited above. Obesity has become so commonplace in the United States that thin, healthy individuals are becoming the exception rather than the rule. With the rising prevalence and incidence of obesity in our society, patients have begun seeing this state of body habitus as the norm rather than the exception. “What's the matter with being a little overweight, doc; everyone in my family is fat, so why not me?”

In response, I deliver my “fat” talk. In this sermonette on obesity, I stress the many increased health risks that overweight individuals incur: atherosclerosis, hypertension, gallstones, diabetes, colonic adenomas, degenerative joint disease, sleep apnea, deep venous thrombosis, and pulmonary embolism, among others. I try to communicate to my obese patients the importance of modest and gradual weight loss as compared with the cycle of rapid weight loss and equally rapid weight gain that is so common in our society. “Bouncing your weight up and down may even put you at greater risk for heart disease,” I continue, hoping that my message will take root in the patient's mind. “Regular exercise such as daily walking is a great help in losing weight. Try to cut back on portion size, simple carbohydrates such as sugar and products made with white flour, as well as saturated fat in your diet. Would you like to speak with one of our dieticians?”

My daily preaching often goes unheeded and leads me and my internal medicine colleagues to become cynical about the possibility of ever convincing our patients to lose weight. This is, unfortunately, the price to be paid in a society that gratifies itself with every type of food taken in excess combined with widespread physical inactivity. Many of my patients ask about the surgical procedures that can lead to dramatic weight loss. I inform them that these operations carry risk and are really designed only for patients who are massively obese. Fortunately, most of my patients are only 30-50 pounds overweight and not massively obese.

Clinical science and epidemiology have convincingly shown that increasing body mass correlates well with rising blood pressure, lipid levels, and blood glucose, all important atherosclerotic risk factors. In general, the more obese the individual, the worse the combined burden of atherosclerotic risk factors. However, obesity alone is not a perfect predictor of atherosclerotic disease risk. For example, a number of epidemiological studies have shown that obesity alone is not a major predictor of coronary heart disease death once more prominent atherosclerotic risk factors that correlate with obesity have been removed. Thus, an obese person with normal values for blood pressure, serum lipids, and blood glucose is not at major risk for the development of atherosclerotic arterial disease. The most important issue to be considered in patients who are overweight is not weight per se, but rather the metabolic consequences of obesity.

As noted earlier, obese patients are at risk for many other health problems. Thus, an obese patient who is normotensive, normolipemic, and euglycemic might still develop severe, crippling degenerative arthritis or sleep apnea as a result of his/her adiposity. Consequently, physicians, including internists and other primary care providers, as well as specialists such as cardiologists, rheumatologists, endocrinologists, gastroenterologists, and other internal medicine specialists, need to look at the entire picture of a particular obese patient's health and not just his/her risk for coronary artery disease. Indeed, physicians should not reassure obese patients about their future health if their atherosclerotic risk factors are normal, because other disease entities might come to plague such patients in the future.

It is important that modest weight loss in an obese patient with atherosclerotic risk factors can result in remarkable improvement in these risk factors. Indeed, it has often been observed that modest (~10% of body weight) loss of weight produces marked amelioration in elevated blood pressure, abnormal serum cholesterol, and glucose intolerance. Moreover, demanding that a patient try to reach his/her ideal body weight is often unrealistic and discourages compliance with the prescribed program of diet and exercise. In the end, “the enemy of good is perfect,” that is, we should strive to enlist our patients in a program that produces moderate, sustained weight loss rather than advising a draconian strategy that will almost certainly fail.

The National Task Force on the Prevention and Treatment of Obesity advises that the best strategy for weight loss is one of moderate caloric restriction, increased activity (that is, regular exercise), and a supportive program of behavioral modification to assist patients in remodeling their eating habits and style (1).

As always, I welcome your comments on our blog.

1) National Task Force on the Prevention and Treatment of Obesity. Dieting and the development of eating disorders in overweight and obese adults. Arch Intern Med. 2000;160:2581–2589.

-- Joseph S. Alpert, MD, editor-in-chief

This article was originally published in the January 2010 issue of The American Journal of Medicine.

Senin, 04 Januari 2010

A Fall in Ghana

Presentation
A fall marked the beginning of a perilous medical journey for a 34-year-old man. He had traveled from the United States, where he lives with his family, to Accra, Ghana for business purposes and was well until the ninth day of his trip, when he fell and twisted his lower back. Although he was able to stand immediately afterwards, the back pain worsened as the morning progressed and was then compounded by malaise, leading him to spend the remainder of the day in bed. He had no neurologic deficits or loss of bowel or bladder continence.

That evening, the patient developed a fever of 102.1° F (38.9° C) with chills and progressive malaise. His health status began to rapidly deteriorate, and he was evacuated to the United States the following day. En route he developed hypoxia, which was corrected with supplemental oxygen. Tachycardia and hypotension responded to intravenous fluid. Upon arrival, he was evaluated at a community hospital, where he received empiric ceftriaxone. He was determined to be in critical condition and was transferred urgently to the intensive care unit (ICU) of the National Naval Medical Center in Bethesda, Md for further management.

Previously healthy, the patient had an unremarkable medical history. A systems review revealed no further complaints, and he had been fully compliant with his malaria prophylaxis. Throughout his stay in Ghana, he had no contact with sick people, animal exposure, or insect bites. He did not leave the luxury hotel complex and only ate approved prepared meals, except for 1 dinner on day 3, which took place at a high-end restaurant with colleagues. His vaccinations were current.

To read this article in its entirety, please visit our website.

-- Michael Eberlein, MD, PhD, Mayy F. Chahla, MD, Sammy A. Baierlein, MD, Richard T. Mahon, MD

This article was originally published in the December 2009 issue of The American Journal of Medicine.

Jumat, 01 Januari 2010

Hospital Computing and the Costs and Quality of Care: A National Study

Abstract
Background


Many believe that computerization will improve health care quality, reduce costs, and increase administrative efficiency. However, no previous studies have examined computerization's cost and quality impacts at a diverse national sample of hospitals.

Methods

We linked data from an annual survey of computerization at approximately 4000 hospitals for the period from 2003 to 2007 with administrative cost data from Medicare Cost Reports and cost and quality data from the 2008 Dartmouth Health Atlas. We calculated an overall computerization score and 3 subscores based on 24 individual computer applications, including the use of computerized practitioner order entry and electronic medical records. We analyzed whether more computerized hospitals had lower costs of care or administration, or better quality. We also compared hospitals included on a list of the “100 Most Wired” with others.

Results

More computerized hospitals had higher total costs in bivariate analyses (r=0.06, P=.001) but not multivariate analyses (P=.69). Neither overall computerization scores nor subscores were consistently related to administrative costs, but hospitals that increased computerization faster had more rapid administrative cost increases (P=.0001). Higher overall computerization scores correlated weakly with better quality scores for acute myocardial infarction (r=0.07, P=.003), but not for heart failure, pneumonia, or the 3 conditions combined. In multivariate analyses, more computerized hospitals had slightly better quality. Hospitals on the “Most Wired” list performed no better than others on quality, costs, or administrative costs.

Conclusion

As currently implemented, hospital computing might modestly improve process measures of quality but does not reduce administrative or overall costs.

To read this article in its entirety, please visit our website.

-- David U. Himmelstein, MD, Adam Wright, PhD, Steffie Woolhandler, MD, MPH

This article originally appeared in the January 2010 issue of The American Journal of Medicine.